Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06024499 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Trial of HY209gel in Atopic Dermatitis Patients
A Phase 2 study of Atopic Dermatitis and Atopic Dermatitis Eczema, sponsored by Shaperon.
- Active
- Registry status
- Phase 2
- Development phase
- 210
- Enrollment target
- 12
- Study locations
NCT06024499: Active Phase 2 study of Atopic Dermatitis and Atopic Dermatitis Eczema, sponsored by Shaperon.
NCT06024499 is a Phase 2 study of Atopic Dermatitis and Atopic Dermatitis Eczema that is active but no longer recruiting, run by Shaperon. The registered enrollment target is 210 participants, below the 608-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (65% lower). The trial reports 12 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06024499, a Phase 2 study of Atopic Dermatitis and Atopic Dermatitis Eczema, is active but no longer recruiting, sponsored by Shaperon.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 210 participants
- Enrollment target
- 12
- Study locations
Study Summary
This is a randomized, double-blind, placebo-controlled, multi-center, phase 2 study in patients with mild to moderate Atopic Dermatitis(AD), which consists of 2 parts.
Primary Outcome
To achieve lower score means disease improvement .
Conditions Studied
Interventions
- OTHER Placebo
- DRUG HY209GEL Active
Study Locations (12)
Other
- Gachon University Gil Medical Center - Seoul
- Seoul National University Bundang Hospital - Seoul
- Seoul National University Hospital - Seoul
- Severance Hospital, Yonsei University Health System - Seoul
California
- RAOOF MD Dermatology - Encino
- L.A. Universal Research Center, Inc. - Los Angeles
- Zenith Research Inc. - Los Angeles
Alabama
- Cahaba Dermatology Skin Health Center - Birmingham
Maryland
- Continental Clinical Solutions, LLC - Towson
Michigan
- Revival Research Institute, LLC - Southfield
New York
- Sadick Dermatology - New York
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Start Date | 2024-03-01 |
| Est. Completion | 2026-08-31 |
| Phase | Phase 2 |
What the registry record for NCT06024499 still lists
NCT06024499 is an interventional study that assigns participants to a tested intervention. The registered 210 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (65% lower).
The record links to 3 conditions, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06024499 lists 12 locations in 7 states (Other, California, Alabama).
Frequently Asked Questions
What is clinical trial NCT06024499 about?
NCT06024499 is a clinical study titled "Phase 2 Trial of HY209gel in Atopic Dermatitis Patients". This is a randomized, double-blind, placebo-controlled, multi-center, phase 2 study in patients with mild to moderate Atopic Dermatitis(AD), which consists of 2 parts.
What is the current status of trial NCT06024499?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 210 participants. The study started on 2024-03-01. Estimated completion is 2026-08-31.
What conditions does trial NCT06024499 study?
This clinical trial studies the following conditions: Atopic Dermatitis, Atopic Dermatitis Eczema, Atopic Dermatitis of Scalp.
What interventions are being tested in trial NCT06024499?
The interventions under investigation include: Placebo (OTHER), HY209GEL Active (DRUG).
Who is sponsoring clinical trial NCT06024499?
This trial is sponsored by Shaperon, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06024499 being conducted?
This trial has 12 study locations across Alabama, California, Maryland, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06024499's enrollment target sits among peer trials
210 54th of 150 higher than 97 of 150 other Atopic Dermatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atopic Dermatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Cardamom and Topical Roseomonas in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
A Study Evaluating TRIV-509 in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02665923 · 210 participants
Gastric Emptying in Neonates and Infants After Formula Feeding
- NCT03322891 · 210 participants · NA
Improving Health Literacy in African-American Prostate Cancer Patients
- NCT03544489 · 210 participants · Phase 2
Effectiveness of Exercise After an ICD
- NCT04408430 · 210 participants · NA
The MITRAL II Pivotal Trial (Mitral Implantation of TRAnscatheter vaLves).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI